PE20200894A1 - Polipeptidos variantes del factor de crecimiento tipo insulina 1 - Google Patents

Polipeptidos variantes del factor de crecimiento tipo insulina 1

Info

Publication number
PE20200894A1
PE20200894A1 PE2019002049A PE2019002049A PE20200894A1 PE 20200894 A1 PE20200894 A1 PE 20200894A1 PE 2019002049 A PE2019002049 A PE 2019002049A PE 2019002049 A PE2019002049 A PE 2019002049A PE 20200894 A1 PE20200894 A1 PE 20200894A1
Authority
PE
Peru
Prior art keywords
insulin
growth factor
variant polypeptides
relates
polypeptides
Prior art date
Application number
PE2019002049A
Other languages
English (en)
Spanish (es)
Inventor
Mara Fornaro
Thomas Huber
Mauro Zurini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200894(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20200894A1 publication Critical patent/PE20200894A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2019002049A 2012-12-18 2013-12-16 Polipeptidos variantes del factor de crecimiento tipo insulina 1 PE20200894A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
PE20200894A1 true PE20200894A1 (es) 2020-09-08

Family

ID=50073229

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002049A PE20200894A1 (es) 2012-12-18 2013-12-16 Polipeptidos variantes del factor de crecimiento tipo insulina 1
PE2015001039A PE20151612A1 (es) 2012-12-18 2013-12-16 Polipeptidos estabilizados del factor de crecimiento tipo insulina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015001039A PE20151612A1 (es) 2012-12-18 2013-12-16 Polipeptidos estabilizados del factor de crecimiento tipo insulina

Country Status (36)

Country Link
US (1) US10167329B2 (https=)
EP (2) EP3626735A1 (https=)
JP (1) JP6499080B2 (https=)
KR (1) KR102182523B1 (https=)
CN (1) CN105121462B (https=)
AP (1) AP2015008440A0 (https=)
AU (1) AU2013365796B2 (https=)
BR (1) BR112015013708B1 (https=)
CA (1) CA2894976C (https=)
CL (1) CL2015001708A1 (https=)
CR (2) CR20200079A (https=)
CU (1) CU24308B1 (https=)
CY (1) CY1122309T1 (https=)
DK (1) DK2935320T3 (https=)
EA (1) EA034356B1 (https=)
EC (1) ECSP15031046A (https=)
ES (1) ES2756330T3 (https=)
GT (1) GT201500168A (https=)
HR (1) HRP20191965T1 (https=)
HU (1) HUE047386T2 (https=)
IL (1) IL239387A0 (https=)
LT (1) LT2935320T (https=)
MA (1) MA38153B1 (https=)
MX (1) MX363021B (https=)
MY (1) MY174820A (https=)
NZ (1) NZ708091A (https=)
PE (2) PE20200894A1 (https=)
PH (1) PH12015501271A1 (https=)
PL (1) PL2935320T3 (https=)
PT (1) PT2935320T (https=)
RS (1) RS59545B1 (https=)
SA (1) SA515360603B1 (https=)
SG (1) SG11201503782PA (https=)
SI (1) SI2935320T1 (https=)
TN (1) TN2015000182A1 (https=)
WO (1) WO2014097116A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271265A1 (en) * 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
SG11201807400TA (en) * 2016-03-04 2018-09-27 Shire Human Genetic Therapies Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP4606428A3 (en) * 2018-06-27 2025-11-05 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
WO2025106529A2 (en) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子(igf)i変異体
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
JP4988599B2 (ja) 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Igf−1融合ポリペプチドおよびその治療的使用
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
PL3075858T3 (pl) 2007-12-21 2020-07-13 Novartis Ag Ssaczy wektor ekspresyjny
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Also Published As

Publication number Publication date
AP2015008440A0 (en) 2015-05-31
MA38153B1 (fr) 2018-06-29
CU20150064A7 (es) 2016-02-29
US20150329614A1 (en) 2015-11-19
NZ708091A (en) 2018-03-23
KR102182523B1 (ko) 2020-11-25
GT201500168A (es) 2016-01-21
CU24308B1 (es) 2018-01-10
PT2935320T (pt) 2019-11-15
CR20150324A (es) 2015-08-10
HUE047386T2 (hu) 2020-04-28
EA201591165A1 (ru) 2015-11-30
SG11201503782PA (en) 2015-06-29
ES2756330T3 (es) 2020-04-27
EP2935320B1 (en) 2019-08-21
JP2016501025A (ja) 2016-01-18
AU2013365796B2 (en) 2017-03-30
JP6499080B2 (ja) 2019-04-10
ECSP15031046A (es) 2019-03-29
MY174820A (en) 2020-05-17
AU2013365796A1 (en) 2015-05-28
PL2935320T3 (pl) 2020-03-31
EP3626735A1 (en) 2020-03-25
IL239387A0 (en) 2015-07-30
CN105121462B (zh) 2019-08-02
CY1122309T1 (el) 2021-01-27
CL2015001708A1 (es) 2015-08-28
BR112015013708B1 (pt) 2022-10-18
US10167329B2 (en) 2019-01-01
LT2935320T (lt) 2019-11-11
CR20200079A (es) 2020-03-21
EA034356B1 (ru) 2020-01-30
MX2015007932A (es) 2015-10-05
RS59545B1 (sr) 2019-12-31
HK1212712A1 (en) 2016-06-17
TN2015000182A1 (en) 2016-10-03
CA2894976A1 (en) 2014-06-26
HRP20191965T1 (hr) 2020-01-24
CN105121462A (zh) 2015-12-02
PE20151612A1 (es) 2015-11-19
SA515360603B1 (ar) 2020-07-26
MX363021B (es) 2019-03-05
PH12015501271B1 (en) 2015-08-24
BR112015013708A2 (pt) 2017-11-14
DK2935320T3 (da) 2019-11-18
SI2935320T1 (sl) 2019-12-31
EP2935320A1 (en) 2015-10-28
PH12015501271A1 (en) 2015-08-24
KR20150095879A (ko) 2015-08-21
MA38153A1 (fr) 2016-06-30
CA2894976C (en) 2022-10-04
WO2014097116A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
PE20200894A1 (es) Polipeptidos variantes del factor de crecimiento tipo insulina 1
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
AR087973A1 (es) Variantes del factor 21 del crecimiento de fibroblastos
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
CU20140034A7 (es) Proteínas de fusión para tratar trastornos metabólicos
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201291234A1 (ru) Аналоги глюкагона
BR112012021329A2 (pt) anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo.
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX342313B (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
EA201690490A1 (ru) Миметики инсулиноподобного фактора роста для применения в терапии
MX2019008961A (es) Composicion intranasal que comprende betahistina.
WO2014142760A3 (en) Re-trafficking of herg reverses long qt syndrome 2 phenotype in human ips-derived cardiomyocytes
PE20160877A1 (es) Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion
CU20160082A7 (es) Un proceso para la preparación de una composición de proteínas pegiladas